AVAPRO 300 MG
IRBESARTAN : 300 MG · DIN 02237925 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is AVAPRO?
AVAPRO 300 MG contains IRBESARTAN : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02237925, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 03-May-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AVAPRO used for?
Treatment of essential hypertension. Hypertensive patients with type 2 diabetes mellitus and renal disease to reduce the rate of progression of nephropathy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02237925 |
|---|---|
| Brand name | AVAPRO |
| Generic / active ingredient | IRBESARTAN : 300 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09CA04 IRBESARTAN |
| AHFS class | 24:32.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-May-2007 |
| Original market date | 1998-07-22 00:00:00 |
How is it administered?
Essential hypertension/diabetic renal disease: Initial 150 mg once daily; may increase to 300 mg. Hemodialysis or volume-depleted patients: Initial 75 mg. May be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard USP/Canadian practice, though specific section 11 text was truncated in snippet, the header exists).
How is it supplied?
Bottles of 90 tablets.
Contraindications
Hypersensitivity; co-administration with aliskiren in diabetes or renal impairment; co-administration with ACEIs in diabetic nephropathy; hereditary galactose intolerance; pregnancy; breastfeeding.
Warnings and precautions
Fetal toxicity (Serious Warning); Hypotension in volume-depleted patients; Dual blockade of RAS; Renal function impairment; Intestinal angioedema; Hypoglycemia; Psoriasis exacerbation.
Is IRBESARTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09CA04 IRBESARTAN. 38 of 103 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-IRBESARTAN | 150 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02548224 |
| AG-IRBESARTAN | 300 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02548232 |
| AG-IRBESARTAN | 75 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02548216 |
| AVAPRO | 150 MG | TABLET | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02237924 |
| IRBESARTAN | 150 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02372371 |
| IRBESARTAN | 150 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02365200 |
| IRBESARTAN | 150 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385295 |
| IRBESARTAN | 300 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02365219 |
| IRBESARTAN | 300 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02372398 |
| IRBESARTAN | 300 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385309 |
Who else supplies IRBESARTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IRBESARTAN appears in 1256 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.